MESO•benzinga•
Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges
Summary
Mesoblast's Ryoncil is now FDA-approved for pediatric SR-aGvHD, marking a milestone in mesenchymal stromal cell therapies in the U.S.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 19, 2024 by benzinga